<?xml version='1.0' encoding='utf-8'?>
<document id="15344842"><sentence text="Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase."><entity charOffset="55-67" id="DDI-PubMed.15344842.s1.e0" text="pitavastatin" /></sentence><sentence text="To gain a better understanding of the metabolic stability and transport of pitavastatin (CAS 147526-32-7), a new and potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, experiments were conducted using human hepatocytes and oocytes of Xenopus laevis expressing human organic anion transporting polypeptide-2 (OATP2), respectively"><entity charOffset="75-87" id="DDI-PubMed.15344842.s2.e0" text="pitavastatin" /></sentence><sentence text=" Almost the entire radioactivity was from the unchanged substance or lactone form in human hepatocytes, and the cytochrome P450 (CYP)-mediated metabolism of pitavastatin was negligible"><entity charOffset="69-76" id="DDI-PubMed.15344842.s3.e0" text="lactone" /><entity charOffset="157-169" id="DDI-PubMed.15344842.s3.e1" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.15344842.s3.e0" e2="DDI-PubMed.15344842.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15344842.s3.e0" e2="DDI-PubMed.15344842.s3.e1" /></sentence><sentence text=" The results suggested that CYPs are not critically involved in determining the metabolic fate of pitavastatin"><entity charOffset="98-110" id="DDI-PubMed.15344842.s4.e0" text="pitavastatin" /></sentence><sentence text=" The hepatic uptake of pitavastatin reached saturation with a Km of 2"><entity charOffset="23-35" id="DDI-PubMed.15344842.s5.e0" text="pitavastatin" /></sentence><sentence text="99 +/- 0" /><sentence text="79 micromol/L" /><sentence text=" Also, the uptake of pitavastatin was mediated by OATP2 expressed in oocytes with a Km of 5"><entity charOffset="21-33" id="DDI-PubMed.15344842.s8.e0" text="pitavastatin" /></sentence><sentence text="53 +/- 1" /><sentence text="70 micromol/L" /><sentence text=" These results indicated that OATP2 plays a major role in the distribution of pitavastatin in liver"><entity charOffset="78-90" id="DDI-PubMed.15344842.s11.e0" text="pitavastatin" /></sentence><sentence text=" Furthermore, to elucidate the increase in the plasma concentration of pitavastatin in a clinical setting, the inhibitory effect of ciclosporin (cyclosporin A, CAS 59865-13-3) on the uptake of pitavastatin was examined"><entity charOffset="71-83" id="DDI-PubMed.15344842.s12.e0" text="pitavastatin" /><entity charOffset="132-143" id="DDI-PubMed.15344842.s12.e1" text="ciclosporin" /><entity charOffset="145-158" id="DDI-PubMed.15344842.s12.e2" text="cyclosporin A" /><entity charOffset="193-205" id="DDI-PubMed.15344842.s12.e3" text="pitavastatin" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e0" e2="DDI-PubMed.15344842.s12.e0" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e0" e2="DDI-PubMed.15344842.s12.e1" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e0" e2="DDI-PubMed.15344842.s12.e2" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e0" e2="DDI-PubMed.15344842.s12.e3" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e1" e2="DDI-PubMed.15344842.s12.e1" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e1" e2="DDI-PubMed.15344842.s12.e2" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e1" e2="DDI-PubMed.15344842.s12.e3" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e2" e2="DDI-PubMed.15344842.s12.e2" /><pair ddi="false" e1="DDI-PubMed.15344842.s12.e2" e2="DDI-PubMed.15344842.s12.e3" /></sentence><sentence text=" The uptake of pitavastatin was inhibited in the presence of cyclosporin A and the apparent IC50 value was 2"><entity charOffset="15-27" id="DDI-PubMed.15344842.s13.e0" text="pitavastatin" /><entity charOffset="61-74" id="DDI-PubMed.15344842.s13.e1" text="cyclosporin A" /><pair ddi="false" e1="DDI-PubMed.15344842.s13.e0" e2="DDI-PubMed.15344842.s13.e0" /><pair ddi="false" e1="DDI-PubMed.15344842.s13.e0" e2="DDI-PubMed.15344842.s13.e1" /></sentence><sentence text="91 +/- 0" /><sentence text="78 micromol/L" /><sentence text=" This result may at least partly explain the drug-drug interaction between pitavastatin and cyclosporin A"><entity charOffset="75-87" id="DDI-PubMed.15344842.s16.e0" text="pitavastatin" /><entity charOffset="92-105" id="DDI-PubMed.15344842.s16.e1" text="cyclosporin A" /><pair ddi="false" e1="DDI-PubMed.15344842.s16.e0" e2="DDI-PubMed.15344842.s16.e0" /><pair ddi="false" e1="DDI-PubMed.15344842.s16.e0" e2="DDI-PubMed.15344842.s16.e1" /></sentence><sentence text=" In conclusion, the characterization of transporters needs to be taken into account to avoid transporter-mediated drug-drug interaction" /><sentence text="" /></document>